Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure.

ABSTRACT: The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high. Current therapy is effective at achieving on-treatment, but not off-treatment, viral suppression. Loss of hepatitis B surface antigen, the best surrogate marker of off-treatment viral suppression, is associated with improved clinical outcomes. Unfortunately, this end point is rarely achieved with current therapy because of their lack of effect on covalently closed circular DNA, the template of viral transcription and genome replication. Major advancements in our understanding of HBV virology along with better understanding of immunopathogenesis have led to the development of a multitude of novel therapeutic approac

SUBMITTER: Yardeni D 

PROVIDER: S-EPMC9772068 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature